Florfenicol (FFC) has recently been approved by the Food and Drug Administration for the treatment of several bacterial diseases of cultured fish species in the United States, including enteric septicemia of catfish (ESC) caused by Edwardsiella ictaluri. The FFC-resistant E. ictaluri strain (M07-1) described herein was isolated from a moribund catfish obtained from the Thad Cochran National Warmwater Aquaculture Research Center (Stoneville, MS) in May of 2007 and was confirmed to be E. ictaluri by 16S rRNA gene sequencing (6). Fish showing signs of ESC were examined for FFC-resistant E. ictaluri because losses due to ESC persisted in this population despite FFC treatment. To characterize the resistance properties of this strain, conjugative transfer experiments were performed as described previously (14) using FFC (30 g/ml) for selection. The antimicrobial susceptibilities of M07-1, the corresponding FFCresistant transconjugant, and the isogenic parent strain (Table 1) were quantified using standard microdilution assays (3, 4, 11), demonstrating that the resistance phenotype observed in strain M07-1 was self-transmissible, conferring resistance to FFC, chloramphenicol, tetracycline, streptomycin, ampicillin, amoxicillin-clavulanic acid, ceftiofur, and cefoxitin, as well as decreased susceptibility to trimethoprim-sulfamethoxazole and ceftriaxone. Resistance transfer correlated to a 150-kb plasmid (referred to hereinafter as pM07-1), suggesting the presence of a multidrug resistance plasmid in this isolate (data not shown). PCR analysis (15) followed by sequencing confirmed that E. ictaluri M07-1 and its multidrugresistant (MDR) transconjugant harbored the floR gene.
M07-1 and its correlation with plasmid pM07-1 transfer. The bla CMY-2 amplicon was detected in M07-1 and in the corresponding FFC-selected Escherichia coli transconjugant and was 100% identical to previously described plasmidcarried bla CMY-2 genes in Salmonella enterica, E. coli, and Klebsiella pneumoniae.
There have been several reports of IncA/C plasmids from various Salmonella and E. coli strains that harbor the bla CMY-2 gene and more recent reports of IncA/C plasmids harboring both bla CMY-2 and floR in human clinical isolates of Salmonella serovar Newport (7, 14) and in an isolate of the fish pathogen Aeromonas salmonicida subsp. salmonicida from Atlantic salmon in Canada (10) . IncA/C MDR plasmids have also been identified in a human clinical isolate of Yersinia pestis from Madagascar and in several clinical isolates of Vibrio cholerae O139 from China (12, 14) . Plasmid pM07-1 was evaluated for the presence of the IncA/C backbone by using 13 backbonespecific PCR assays as described previously (14) . Both the M07-1 parent strain and the E. coli transconjugant harboring pM07-1 were positive for all 13 IncA/C plasmid markers examined, thus providing definitive evidence that plasmid pM07-1 is a member of the IncA/C family.
This report documents the first case of FFC resistance in the catfish pathogen E. ictaluri. Interpretive standards for FFC sensitivity testing of E. ictaluri have not yet been established; however, the MIC for E. ictaluri M07-1 (128 g/ml) was approximately 500 times higher than the average MIC determined for susceptible strains of E. ictaluri (9) , suggesting that strains carrying plasmid pM07-1 would be less likely to respond clinically to FFC treatment. It is also important to emphasize that plasmid pM07-1 confers decreased susceptibility to all three antimicrobial drugs that are currently approved for use in aquaculture in the United States (FFC, ormetoprim-sulfadimethoxine, and oxytetracycline) and that, therefore, should further dissemination of the pM07-1 plasmid occur, it could have a profound effect on the performance of therapeutic antimicrobial drugs in U.S. aquaculture.
Nucleotide sequence accession numbers. The sequences of floR and bla CMY-2 determined in this study have been deposited in GenBank under accession numbers FJ438528 and FJ438529. 
